Evolving Treatment Patterns in Diabetic Macular Edema Between 2015 and 2020
© The Author(s) 2023..
Purpose: To explore the recent evolution of diabetic macular edema (DME) treatment practice patterns over 5 years among retina specialists in the United States. Methods: This retrospective analysis assessed 306 700 eyes with newly diagnosed DME from the Vestrum Health database between January 2015 and October 2020. The year-over-year and cumulative 5-year distributions of eyes treated with antivascular endothelial growth factor (anti-VEGF) agents, steroids, focal laser, or any combination and those of untreated eyes were calculated. Changes from baseline visual acuity were assessed. Results: Yearly treatment patterns changed significantly from 2015 (n = 18056) to 2020 (n = 11042). The proportion of untreated patients declined over time (32.7% vs 27.7%; P < .001), the use of anti-VEGF monotherapy increased (43.5% vs 61.8%; P < .001), the use of focal laser monotherapy declined (9.7% vs 3.0%; P < .001), and the use of steroid monotherapy remained stable (0.9% vs 0.7%; P = 1.000). Of eyes that maintained follow-up for 5 years (from 2015 to 2020), 16.3% were untreated while 77.5% were treated with anti-VEGF agents (as monotherapy or combination therapy). Vision gains in treated patients remained approximately stable from 2015 (3.6 letters) to 2020 (3.5 letters). Conclusions: From 2015 to 2020, treatment patterns for DME evolved toward greater anti-VEGF monotherapy, stable steroid monotherapy, less laser monotherapy, and fewer untreated eyes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Journal of vitreoretinal diseases - 7(2023), 3 vom: 01. Mai, Seite 199-202 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sodhi, Guneet S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-VEGF |
|---|
| Anmerkungen: |
Date Revised 03.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/24741264231156096 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35690878X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35690878X | ||
| 003 | DE-627 | ||
| 005 | 20240303231829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/24741264231156096 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1315.xml |
| 035 | |a (DE-627)NLM35690878X | ||
| 035 | |a (NLM)37188218 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sodhi, Guneet S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evolving Treatment Patterns in Diabetic Macular Edema Between 2015 and 2020 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. | ||
| 520 | |a Purpose: To explore the recent evolution of diabetic macular edema (DME) treatment practice patterns over 5 years among retina specialists in the United States. Methods: This retrospective analysis assessed 306 700 eyes with newly diagnosed DME from the Vestrum Health database between January 2015 and October 2020. The year-over-year and cumulative 5-year distributions of eyes treated with antivascular endothelial growth factor (anti-VEGF) agents, steroids, focal laser, or any combination and those of untreated eyes were calculated. Changes from baseline visual acuity were assessed. Results: Yearly treatment patterns changed significantly from 2015 (n = 18056) to 2020 (n = 11042). The proportion of untreated patients declined over time (32.7% vs 27.7%; P < .001), the use of anti-VEGF monotherapy increased (43.5% vs 61.8%; P < .001), the use of focal laser monotherapy declined (9.7% vs 3.0%; P < .001), and the use of steroid monotherapy remained stable (0.9% vs 0.7%; P = 1.000). Of eyes that maintained follow-up for 5 years (from 2015 to 2020), 16.3% were untreated while 77.5% were treated with anti-VEGF agents (as monotherapy or combination therapy). Vision gains in treated patients remained approximately stable from 2015 (3.6 letters) to 2020 (3.5 letters). Conclusions: From 2015 to 2020, treatment patterns for DME evolved toward greater anti-VEGF monotherapy, stable steroid monotherapy, less laser monotherapy, and fewer untreated eyes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-VEGF | |
| 650 | 4 | |a antivascular endothelial growth factor injection | |
| 650 | 4 | |a diabetic macular edema | |
| 650 | 4 | |a focal laser therapy | |
| 650 | 4 | |a intravitreal steroids | |
| 700 | 1 | |a Haq, Zeeshan |e verfasserin |4 aut | |
| 700 | 1 | |a Aggarwal, Nitika |e verfasserin |4 aut | |
| 700 | 1 | |a Boucher, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Emerson, Geoffrey G |e verfasserin |4 aut | |
| 700 | 1 | |a Hahn, Paul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of vitreoretinal diseases |d 2017 |g 7(2023), 3 vom: 01. Mai, Seite 199-202 |w (DE-627)NLM272346829 |x 2474-1272 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:3 |g day:01 |g month:05 |g pages:199-202 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/24741264231156096 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 3 |b 01 |c 05 |h 199-202 | ||